Sinusitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Sinusitis – Pipeline Review, H2 2016’, provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Sinusitis

The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects

The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Sinusitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sinusitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AmpliPhi Biosciences Corporation

F. Hoffmann-La Roche Ltd.

Knopp Biosciences LLC

Kyorin Pharmaceutical Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

Merck & Co., Inc.

Oticpharma Ltd

Paratek Pharmaceuticals, Inc.

Pfizer Inc.

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Therabron Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Sinusitis Overview 7

Therapeutics Development 8

Pipeline Products for Sinusitis - Overview 8

Sinusitis - Therapeutics under Development by Companies 9

Sinusitis - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Sinusitis - Products under Development by Companies 14

Sinusitis - Companies Involved in Therapeutics Development 15

AmpliPhi Biosciences Corporation 15

F. Hoffmann-La Roche Ltd. 16

Knopp Biosciences LLC 17

Kyorin Pharmaceutical Co., Ltd. 18

Kyowa Hakko Kirin Co., Ltd. 19

Merck & Co., Inc. 20

Oticpharma Ltd 21

Paratek Pharmaceuticals, Inc. 22

Pfizer Inc. 23

Quorum Innovations LLC 24

Regeneron Pharmaceuticals Inc 25

Therabron Therapeutics, Inc. 26

Sinusitis - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

ABSA-01 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

benralizumab - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CG-201 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

dexpramipexole dihydrochloride - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

dupilumab - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

fluticasone propionate - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

KRPAM-1977X - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

omadacycline tosylate - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

omalizumab - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

P-008 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

PCL-1404 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

PF-06817024 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Qi-117 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

RG-6149 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecule for Sinusitis - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Sinusitis and Allergic Rhinitis - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecules for Chronic Rhinosinusitis - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

solithromycin - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Sinusitis - Dormant Projects 86

Sinusitis - Product Development Milestones 87

Featured News & Press Releases 87

Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress 87

Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus 87

Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort 88

Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab 88

Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association 89

Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01 89

Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections 90

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 90

Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 91

Appendix 92

Methodology 92

Coverage 92

Secondary Research 92

Primary Research 92

Expert Panel Validation 92

Contact Us 92

Disclaimer 93

List of Tables

List of Tables

Number of Products under Development for Sinusitis, H2 2016 8

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Sinusitis – Pipeline by AmpliPhi Biosciences Corporation, H2 2016 15

Sinusitis – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16

Sinusitis – Pipeline by Knopp Biosciences LLC, H2 2016 17

Sinusitis – Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 18

Sinusitis – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 19

Sinusitis – Pipeline by Merck & Co., Inc., H2 2016 20

Sinusitis – Pipeline by Oticpharma Ltd, H2 2016 21

Sinusitis – Pipeline by Paratek Pharmaceuticals, Inc., H2 2016 22

Sinusitis – Pipeline by Pfizer Inc., H2 2016 23

Sinusitis – Pipeline by Quorum Innovations LLC, H2 2016 24

Sinusitis – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 25

Sinusitis – Pipeline by Therabron Therapeutics, Inc., H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Stage and Target, H2 2016 29

Number of Products by Stage and Mechanism of Action, H2 2016 31

Number of Products by Stage and Route of Administration, H2 2016 33

Number of Products by Stage and Molecule Type, H2 2016 35

Sinusitis – Dormant Projects, H2 2016 86

List of Figures

List of Figures

Number of Products under Development for Sinusitis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 27

Number of Products by Top 10 Targets, H2 2016 28

Number of Products by Stage and Top 10 Targets, H2 2016 28

Number of Products by Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30

Number of Products by Routes of Administration, H2 2016 32

Number of Products by Stage and Routes of Administration, H2 2016 32

Number of Products by Molecule Types, H2 2016 34

Number of Products by Stage and Molecule Types, H2 2016 34


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports